Last reviewed · How we verify
Cilostazol / Ginko Leaf Dried Ext.
This combination therapy inhibits platelet aggregation via phosphodiesterase-3 inhibition (cilostazol) while enhancing microcirculation and reducing blood viscosity through flavonoid and terpenoid components (ginkgo leaf extract).
This combination therapy inhibits platelet aggregation via phosphodiesterase-3 inhibition (cilostazol) while enhancing microcirculation and reducing blood viscosity through flavonoid and terpenoid components (ginkgo leaf extract). Used for Peripheral arterial occlusive disease / intermittent claudication, Cerebrovascular disease / stroke prevention.
At a glance
| Generic name | Cilostazol / Ginko Leaf Dried Ext. |
|---|---|
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | Antiplatelet agent combination / Herbal supplement combination |
| Target | Phosphodiesterase-3 (cilostazol component); multiple targets including platelet aggregation pathways and vascular endothelial function (ginkgo component) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Cilostazol works as a phosphodiesterase-3 inhibitor to increase cAMP levels in platelets and vascular smooth muscle, reducing platelet aggregation and promoting vasodilation. Ginkgo biloba leaf extract contains flavonoids and ginkgolides that improve blood flow, reduce platelet activation, and provide antioxidant effects. Together, they aim to improve peripheral circulation and reduce thrombotic events.
Approved indications
- Peripheral arterial occlusive disease / intermittent claudication
- Cerebrovascular disease / stroke prevention
Common side effects
- Headache
- Diarrhea
- Palpitations
- Dizziness
- Bleeding risk (minor)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: